## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances**
- Source: Zenopa | 20251208T220859 | Bullish | Relevance: 99%
- Orchestra BioMed and Medtronic announced significant advancements in their Atrioventricular Interval Modulation (AVIM) Therapy for uncontrolled hypertension at the 2025 Innovation in Cardiology Intervention (ICI) meeting. This cutting-edge bioelectronic treatment, which can be delivered via a pacemaker firmware upgrade, has received FDA Breakthrough Device Designation and shows promise for millions of patients by offering immediate and sustained blood pressure reductions. The collaboration highlights the potential for transforming hypertension treatment and bringing significant improvements to patient care.

**2. California Public Employees Retirement System Purchases 563,779 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T100754 | Bullish | Relevance: 99%
- The California Public Employees Retirement System (CalPERS) significantly increased its stake in Medtronic PLC, purchasing 563,779 additional shares in Q2 2025, bringing its total holdings to 3,230,852 shares valued at approximately $281.6 million. Medtronic stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44. The company recently surpassed quarterly earnings and revenue estimates and announced a quarterly dividend, indicating strong financial health and positive outlook.

**3. Medtronic PLC $MDT Shares Bought by Cary Street Partners Financial LLC**
- Source: MarketBeat | 20251207T090818 | Bullish | Relevance: 99%
-  Cary Street Partners Financial LLC significantly increased its stake in Medtronic PLC, purchasing an additional 15,663 shares, bringing their total holdings to 97,941 shares valued at $8.54 million. This move aligns with broader institutional interest, as major investors like Vanguard and Norges Bank have also boosted or initiated positions in the medical technology company. Medtronic recently exceeded quarterly earnings estimates, provided strong FY2026 guidance, and declared an attractive quarterly dividend, leading analysts to maintain a "Moderate Buy" consensus rating with a target price of $110.44.

**4. Medtronic (MDT) Upgraded to Buy: Here's Why**
- Source: Yahoo Finance | 20251206T100907 | Bullish | Relevance: 99%
-  Medtronic (MDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. This upgrade is significant for investors as changes in earnings potential are strongly correlated with stock price movements. The Zacks rating system highlights Medtronic's improved business outlook, positioning it in the top 20% of Zacks-covered stocks.

**5. Thematics Asset Management Sells 13,298 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251208T121527 | Bullish | Relevance: 99%
-  Thematics Asset Management reduced its stake in Medtronic PLC by selling 13,298 shares, now holding 184,899 shares valued at $16.12 million; however, many other institutional investors increased their positions. Medtronic reported strong quarterly earnings, beating analyst estimates for EPS and revenue, and announced a quarterly dividend of $0.71. The company's stock has also received updated price targets and ratings from several analyst firms.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.6x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.9B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.6 |
| Current P/E | 17.9 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.7% (minimal 5-day change). Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.71% (CS: 26) | Weak |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | -0.18 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.26
- **Stop Loss:** $97.62 (3.6% risk)
- **Target:** $104.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $13,872.62
- **Portfolio %:** 13.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*